Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2008-8-1
pubmed:abstractText
Fibroblast growth factor receptor 4 (FGFR-4) is expressed at significant levels in almost all human prostate cancers, and expression of its ligands is ubiquitous. A common polymorphism of FGFR-4 in which arginine (Arg(388)) replaces glycine (Gly(388)) at amino acid 388 is associated with progression in human prostate cancer. We show that the FGFR-4 Arg(388) polymorphism, which is present in most prostate cancer patients, results in increased receptor stability and sustained receptor activation. In patients bearing the FGFR-4 Gly(388) variant, expression of Huntingtin-interacting protein 1 (HIP1), which occurs in more than half of human prostate cancers, also results in FGFR-4 stabilization. This is associated with enhanced proliferation and anchorage-independent growth in vitro. Our findings indicate that increased receptor stability and sustained FGFR-4 signaling occur in most human prostate cancers due to either the presence of a common genetic polymorphism or the expression of a protein that stabilizes FGFR-4. Both of these alterations are associated with clinical progression in patients with prostate cancer. Thus, FGFR-4 signaling and receptor turnover are important potential therapeutic targets in prostate cancer.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-10348350, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-10353739, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-10428802, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-10611230, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-10629559, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-10945637, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-11021964, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-11506499, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-11734594, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-11830541, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-12163454, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-12781365, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-14601095, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-14699054, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-14710228, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-14732715, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-15197773, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-15448004, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-15538740, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-15613447, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-15655558, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-15863030, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-16061909, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-16220297, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-16721364, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-16822847, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-16867222, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-16927306, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-16951141, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-17084840, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-17132227, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-17237035, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-17440072, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-17607666, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-17898861, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-8622701, http://linkedlifedata.com/resource/pubmed/commentcorrection/18670643-8663044
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1476-5586
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
847-56
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.
pubmed:affiliation
Department of Pathology, Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural